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APC mutations causing Wnt activation are commonly found in colorectal cancer, but downstream pathways
that facilitate tumorigenesis are unclear. In this issue of Cell Stem Cell, Myant et al. (2013) show that Rac1
activation is required for Wnt-driven Lgr5+ intestinal stem cell transformation through ROS production and
NF-kB activation.Inactivation of the adenomatous polypo-
sis coli (APC) gene is the most common
mutation (70%–80%) in colorectal car-
cinoma (CRC) and is likely the initiating
event in colorectal tumorigenesis (Fearon,
2011). Mutated APC is also crucial for the
maintenance of CRC, because restoration
of wild-type APC expression in CRC cells
with inactive APC alleles either reverts
the transformed phenotype or promotes
apoptosis. APC is a negative regulator of
the Wnt pathway, functioning as a self-
renewal signal for several different types
of adult stem cells (SCs), including intesti-
nal stem cells (ISCs). Notably, inactivation
of Wnt signaling in model systems leads
to loss of ISCs and tissue integrity,
whereas its activation maintains self-
renewal (Fearon, 2011). Wnt signals are
produced locally, from the niche, to main-
tain stemness by favoring self-renewal
and blocking differentiation (Clevers and
Nusse, 2012). b-catenin is a key player in
the signaling output of the Wnt cascade.
In the presence of inactive APC mutants,
as in colon cancer, constitutive activation
of b-catenin signaling occurs.
In this issue of Cell Stem Cell, Myant
and colleagues (Myant et al., 2013) iden-
tify Rac1 as another critical component
of Wnt activation after APC loss in CRC.
Rac1 is a small GTPase that functions
within a variety of intracellular pathways
to regulate cytoskeletal reorganization,
cell migration, proliferation, and survival.
Rac1 has been previously implicated in
cancer (Krauthammer et al., 2012; Zhou
et al., 2013) and in the regulation of the nu-
clear localization of b-catenin (Wu et al.,
2008). Using a number of well-defined
mouse models of colon cancer, including
mice lacking APC and/or Rac1 and miceexpressing mutated Kras, the authors
show that Rac1 is activated in CRC, at
all stages of tumor development, and
that it is indispensable for the mani-
festation of a critical phenotype of APC
loss: increased proliferation of epithelial
cells in the intestinal crypts. Notably,
Rac1 deletion suppresses proliferation of
APC-deficient cells even after experimen-
tally induced activation of Kras, which is
also commonly mutated in CRC. Since
Krasmutation is among themost frequent
mutations associated with progression to
colon cancer, Rac1 might be also crucial
throughout the colon transformation pro-
cess. Surprisingly, the authors observed
that Rac1 is not required for b-catenin nu-
clear localization and/or its functional ac-
tivity in APC absence.
Tumors are heterogeneous pop-
ulations, consisting of cells with or
without tumorigenic properties (respec-
tively termed cancer stem cells [CSCs]
and progenitors). Myant et al. show that
Rac1 deletion suppresses APC inactiva-
tion associated hyperproliferation of
both ISCs and progenitors. Accordingly,
Rac1 deletion prevents ISC transforma-
tion after APC loss. This is particularly
relevant for the value of this pathway as
a target for pharmaceutical intervention.
The targeting of CSCs, in fact, is probably
not sufficient for tumor eradication,
since it is becoming clear that onco-
gene expression in progenitors induces
SC reprogramming, suggesting that can-
cer progenitors contribute to maintaining
the CSC pool (Visvader and Lindeman,
2012). Further levels of heterogeneity
exist in the colon ISCs, where there is ev-
idence for at least two different popula-
tions: one highly proliferative and markedCell Stem Ceby Lgr5, the other relatively quiescent and
marked by BMI1 (Barker et al., 2012). The
authors show that Rac1 is required for
Lgr5+ ISC transformation, but leave the
question open for Bmi1+ cells.
They then identify NF-kB as the down-
stream effector of Rac1 in cells with inac-
tivated APC. Activation of the NK-kB
pathway induces a variety of cellular
behaviors that are consistent with tumor
promoting functions: survival, pro-
liferation, migration, invasion, glycolytic
switch, and angiogenesis. Indeed, NF-
kB activation has been documented in
several tumor types, due to exogenous
signals generated by the tumor microen-
vironment or to somatic mutations of
NF-kB pathway components. Because
NF-kB is a key regulator of inflammation,
it may represent the link between inflam-
mation and tumor development, which is
emerging as a critical connection in all
steps of colon tumorigenesis (Perkins,
2012). The authors observed increased
NF-kB signaling in the APC-inactivated in-
testinal cells, which was dependent on
Rac1 expression. Notably, they demon-
strate that constitutive NF-kB signaling
partially compensates for Rac1 deletion.
Finally, Myant et al. show that reactive
oxygen species (ROS) function as
signaling molecules to connect Rac1
and NF-kB. There is an epistatic interac-
tion between Rac1, ROS, and NF-kB in
different intracellular pathways. Rac1 is
required for NF-kB activation and is part
of a protein complex containing NADPH
oxidase, which generates superoxide, a
major constituent of the pool of intracel-
lular ROS. NF-kB is a redox-sensitive
transcription factor that is activated by
increased levels of ROS. The authorsll 12, June 6, 2013 ª2013 Elsevier Inc. 635
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tivity, ROS intracellular concentration,
and NF-kB signaling in the APC-inacti-
vated intestinal cells are all dependent
on Rac1 expression. By modulating
intracellular ROS levels in vivo through
treatment with antioxidants and pro-
oxidants, they further demonstrate that
Rac1-driven ROS generation is essential
for the effect of APC loss on ISCs and pro-
genitors. In summary, through the elegant
use of various mutant mouse models, the
authors provide evidence that Rac1-
driven ROS production is required for
NF-kB activation and initiation of colon
tumorigenesis.
Although ROS involvement in tumori-
genesis has been known for decades,
ROSwere initially considered a byproduct
of cellular metabolism, contributing to tu-
mor initiation by inducing DNA damage,
e.g., as endogenous mutagenic agents.
More recently, ROS increase and DNA
damage accumulation have been shown
to be invariably associated with expres-
sion of activated oncogenes in normal
cells, a phenomenon that is perceived as
integral to tumor development. There is,
however, a second face to ROS, distinct
from that of damaging agents, which
sees them function as signaling mole-
cules in a variety of intracellular pathways636 Cell Stem Cell 12, June 6, 2013 ª2013 E(Giorgio et al., 2007). Accordingly,
increased ROSmight contribute to tumor-
igenesis by activating specific signaling
pathways, as Myant and colleagues
suggest here for NF-kB and colon
tumorigenesis.
The authors contribute to a further level
of understanding of ROS signaling, i.e. the
cellular context wherein ROS accumula-
tion becomes critical for transformation.
Fine mapping of the identity of tumori-
genic intestinal cells reveals that ROS
levels in the APC-deficient intestine were
particularly high at the crypt base, at cell
positions 1–3 (where Lgr5+ ISCs reside),
suggesting that deregulated ROS
signaling in the proliferating ISCs is critical
to colon tumorigenesis. However, it is also
clear that, under normal conditions,
context-dependent modifications of the
redox balance can influence critical SC
functions, including proliferation, differen-
tiation, and survival. SCs have smaller
mitochondrial DNA copy numbers and
higher expression levels of antioxidant
genes than their differentiated progeny,
which maintain intracellular ROS at low
levels. While this might result in an SC-
specific mechanism to preserve genome
and proteome integrity, it might also allow
tolerance to increased ROS levels, thus
providing SCs with the capacity to endurelsevier Inc.the hyperproliferative effect of ROS. Time
and technologies seem ripe to investigate
the biology of redox changes in SCs.REFERENCES
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Recently in Cell, Mitalipov and colleagues report an advance that has eluded scientists for over a decade—
the successful derivation of embryonic stem cell lines using somatic cell nuclear transfer, or SCNT (Tachibana
et al., 2013).After the isolation and propagation of hu-
man embryonic stem cells (ESCs) was
first reported in 1998, many stem cell
and reproductive biologists set their
sights on being the first to isolate ESCsfrom SCNT-generated (or ‘‘cloned’’) hu-
man embryos. SCNT is a technique where
the nucleus of a somatic cell is inserted
into a recipient oocyte. Then cleavage of
the oocyte containing the donor nucleuscan be induced to initiate embryogenesis,
which is supported by reprogramming
factors in the oocyte. At the time, SCNT
was the only potential source of pluripo-
tent cells genetically matched to an
